Editorial Board

Editors

  • A Cervantes, University of Valencia, Biomedical Research Institute, Inclivia,, Department of Hematology and Medical Oncology, Valencia, Spain, Neurology
  • G. Curigliano, MD, PhD, European Institute of Oncology, Milano, Italy, breast cancer
  • G. Lenz, University Hospital Munster, Münster, Germany, molecular pathogenesis of aggressive lymphoma,   NF-κB pathway,   PI3K/AKT signalling,   tumour microenvironment
  • R.A. Stahel, MD, University of Zurich, Zurich, Switzerland, lung and thoracic oncology

Editorial Board

  • S Aebi, Cantonal Hospital Lucerne Oncology, Luzern, Switzerland, breast cancer and gynecological tumors
  • S. Banerjee, Royal Marsden NHS Foundation Trust, London, United Kingdom, Gynaecological cancers,  ovarian,  endometrial,  cervical cancers,  PARP inhibitors
  • D. Bedognetti, Sidra Medicine, Doha, Qatar, Tumor Biology Immunology
  • J. Bellmunt, MD, Vall d'Hebron Research Institute, Barcelona, Spain, Solid Tumor Oncology (GU & GI)
  • S Bielack, Stuttgart, Germany, pediatric oncology,  adolescents and young adults with cancer,  bone sarcoma 
  • J. Bruix, Clinic Barcelona Hospital University, Barcelona, Spain, hepatocellular carcinoma,  intrahepatic chilangiocarcinoma,  diagnosis and treatment
  • R. Califano, MD, The Christie NHS Foundation Trust, Manchester, United Kingdom, small cell lung cancer and non small cell lung cancer ,  egfr ,  alk and immunotherapy 
  • F. Cardoso, MD, Champalimaud Clinical Centre, Lisboa, Portugal, biology of breast cancer,  prognostic and predictive markers of response to systemic therapy,  and new anticancer agents
  • P. Casali, Foundation IRCCS Carlo Besta Neurological Institute, Milano, Italy, adult sarcomas,  including gastrointestinal stromal tumours
  • A. Chan, The Chinese University of Hong Kong, Hong Kong, Hong Kong, Head and neck cancers,  Nasopharynx cancer,  Epstein Barr Virus
  • R.C. Coleman, MBBS, MD, FRCP, The University of Sheffield, Department of Oncology and Metabolism, Sheffield, United Kingdom, Cancer,  Bone,  Biomarkers,  Bisphosphonates,  Clinical trials
  • D. De Ruysscher, MD, PhD, MAASTRO, Maastricht, Netherlands, radiation oncology
  • C. Dittrich, Klinik Favoriten, Wien, Austria, Methodology of clinical trials,  Clinical trial regulation,  Pancreatic cancer
  • R. Dziadziuszko, MD, PhD, Medical University of Gdansk, Gdansk, Poland
  • T. Eisen, Addenbrooke's Hospital, Cambridge, United Kingdom, Renal cell carcinoma,  Drug development
  • M. Hutchings, Copenhagen, Denmark, lymphoma
  • K Jordan, Ernst von Bergmann Hospital, Potsdam, Germany, Internal Medicine and Haematology and Oncology
  • M. Ladetto, Hemato-Oncology
  • F. Lordick, Leipzig University, Leipzig, Germany, hematology and oncology
  • R.J. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, hematology and oncology
  • O Michielin, National Center of Competence in Research in Molecular Oncology, Lausanne, Switzerland, translational oncology
  • C. Pezaro, Sheffield Teaching Hospitals NHS Foundation Trust, Melbourne, Australia, Genitourinary cancer,  Prostate cancer,  Clinical research,  Translational research.
  • M.R. Posner, The Mount Sinai Hospital, New York, New York, United States of America, Hematology-Oncology,  Cancer (Oncology)
  • A. Prat, University of Barcelona, Barcelona, Spain, breast cancer -omics,  and clinical implementation of omic-based assays. Specialties: Breast Cancer Gene Expression Profiling
  • M. Preusser, Medical University of Vienna,, Department of Medicine I, Division of Oncology, Wein, Austria, characterization of inflammatory infiltrates and immune checkpoint molecules in cancer,   anti-cancer drugs including immunotherapies
  • S.A. Quezada, University College London Medical School, London, United Kingdom, Immune Regulation and Tumour Immunotherapy
  • C. Sessa, University of Bern, Bern, Switzerland, Obstetrics and Gynaecology,  Pharmacology
  • J. Tabernero, MD, Vall d'Hebron Research Institute, Barcelona, Spain, colorectal cancer
  • K. Tamura, National Cancer Center Japan, Chuo-Ku, Japan, Breast and Medical Oncology
  • P Tan, Genome Institute of Singapore, Singapore, Singapore, gastric cancer
  • D. Trapani, MD, European Institute of Oncology, Milano, Italy, Breast cancer, Essential medicines, Selection and prioritization of cancer medicines, National cancer control planning, HTA, cancer policy, global oncology
  • M. Weller, University of Zurich, Zurich, Switzerland, brain tumors and the diagnosis and therapy of glioblastoma and other primary brain tumors.
  • Y.L. Wu, MD, Guangdong Provincial People's Hospital, Guangzhou, China, Multidisciplinary therapy and translational medicine on lung cancer,   Evidence-based medicine in Oncology